BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 22454058)

  • 1. Overview on AON design.
    Aartsma-Rus A
    Methods Mol Biol; 2012; 867():117-29. PubMed ID: 22454058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing RNA/ENA chimeric antisense oligonucleotides using in vitro splicing.
    Takeshima Y; Yagi M; Matsuo M
    Methods Mol Biol; 2012; 867():131-41. PubMed ID: 22454059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional analysis of 114 exon-internal AONs for targeted DMD exon skipping: indication for steric hindrance of SR protein binding sites.
    Aartsma-Rus A; De Winter CL; Janson AA; Kaman WE; Van Ommen GJ; Den Dunnen JT; Van Deutekom JC
    Oligonucleotides; 2005 Dec; 15(4):284-97. PubMed ID: 16396622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exonic sequences provide better targets for antisense oligonucleotides than splice site sequences in the modulation of Duchenne muscular dystrophy splicing.
    Aartsma-Rus A; Houlleberghs H; van Deutekom JC; van Ommen GJ; 't Hoen PA
    Oligonucleotides; 2010 Apr; 20(2):69-77. PubMed ID: 20377429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guidelines for antisense oligonucleotide design and insight into splice-modulating mechanisms.
    Aartsma-Rus A; van Vliet L; Hirschi M; Janson AA; Heemskerk H; de Winter CL; de Kimpe S; van Deutekom JC; 't Hoen PA; van Ommen GJ
    Mol Ther; 2009 Mar; 17(3):548-53. PubMed ID: 18813282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications.
    Aartsma-Rus A; van Ommen GJ
    RNA; 2007 Oct; 13(10):1609-24. PubMed ID: 17684229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative analysis of antisense oligonucleotide analogs for targeted DMD exon 46 skipping in muscle cells.
    Aartsma-Rus A; Kaman WE; Bremmer-Bout M; Janson AA; den Dunnen JT; van Ommen GJ; van Deutekom JC
    Gene Ther; 2004 Sep; 11(18):1391-8. PubMed ID: 15229633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carba-LNA-5MeC/A/G/T modified oligos show nucleobase-specific modulation of 3'-exonuclease activity, thermodynamic stability, RNA selectivity, and RNase H elicitation: synthesis and biochemistry.
    Upadhayaya R; Deshpande SG; Li Q; Kardile RA; Sayyed AY; Kshirsagar EK; Salunke RV; Dixit SS; Zhou C; Földesi A; Chattopadhyaya J
    J Org Chem; 2011 Jun; 76(11):4408-31. PubMed ID: 21500818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective study in the rational design of efficient antisense oligonucleotides for exon skipping in the DMD gene.
    Pramono ZA; Wee KB; Wang JL; Chen YJ; Xiong QB; Lai PS; Yee WC
    Hum Gene Ther; 2012 Jul; 23(7):781-90. PubMed ID: 22486275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo comparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping.
    Heemskerk HA; de Winter CL; de Kimpe SJ; van Kuik-Romeijn P; Heuvelmans N; Platenburg GJ; van Ommen GJ; van Deutekom JC; Aartsma-Rus A
    J Gene Med; 2009 Mar; 11(3):257-66. PubMed ID: 19140108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring the frontiers of therapeutic exon skipping for Duchenne muscular dystrophy by double targeting within one or multiple exons.
    Aartsma-Rus A; Kaman WE; Weij R; den Dunnen JT; van Ommen GJ; van Deutekom JC
    Mol Ther; 2006 Sep; 14(3):401-7. PubMed ID: 16753346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic modulation of DMD splicing by blocking exonic splicing enhancer sites with antisense oligonucleotides.
    Aartsma-Rus A; Janson AA; Heemskerk JA; De Winter CL; Van Ommen GJ; Van Deutekom JC
    Ann N Y Acad Sci; 2006 Oct; 1082():74-6. PubMed ID: 17145928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antisense oligonucleotide-mediated exon skipping of CHRNA1 pre-mRNA as potential therapy for Congenital Myasthenic Syndromes.
    Tei S; Ishii HT; Mitsuhashi H; Ishiura S
    Biochem Biophys Res Commun; 2015 Jun; 461(3):481-6. PubMed ID: 25888793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The therapeutic potential of antisense-mediated exon skipping.
    van Ommen GJ; van Deutekom J; Aartsma-Rus A
    Curr Opin Mol Ther; 2008 Apr; 10(2):140-9. PubMed ID: 18386226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of antisense-mediated exon skipping as a treatment for duchenne muscular dystrophy.
    Heemskerk H; de Winter CL; van Ommen GJ; van Deutekom JC; Aartsma-Rus A
    Ann N Y Acad Sci; 2009 Sep; 1175():71-9. PubMed ID: 19796079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy.
    Aartsma-Rus A; Janson AA; van Ommen GJ; van Deutekom JC
    BMC Med Genet; 2007 Jul; 8():43. PubMed ID: 17612397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exon skipping quantification by real-time PCR.
    Ferlini A; Rimessi P
    Methods Mol Biol; 2012; 867():189-99. PubMed ID: 22454062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DMD pseudoexon mutations: splicing efficiency, phenotype, and potential therapy.
    Gurvich OL; Tuohy TM; Howard MT; Finkel RS; Medne L; Anderson CB; Weiss RB; Wilton SD; Flanigan KM
    Ann Neurol; 2008 Jan; 63(1):81-9. PubMed ID: 18059005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correction of a Cystic Fibrosis Splicing Mutation by Antisense Oligonucleotides.
    Igreja S; Clarke LA; Botelho HM; Marques L; Amaral MD
    Hum Mutat; 2016 Feb; 37(2):209-15. PubMed ID: 26553470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Target selection for antisense oligonucleotide induced exon skipping in the dystrophin gene.
    Errington SJ; Mann CJ; Fletcher S; Wilton SD
    J Gene Med; 2003 Jun; 5(6):518-27. PubMed ID: 12797117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.